Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 14/20 | 0.71 |
| ▸ | NPC1 | O15118 | 7/20 | 0.71 |
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | RAB9A | P51151 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | HTT | P42858 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 1/20 | 0.71 |
| ▸ | MMP2 | P08253 | 4/20 | 0.66 |
| ▸ | MMP9 | P14780 | 4/20 | 0.66 |
| ▸ | MMP8 | P22894 | 4/20 | 0.66 |
| ▸ | MMP13 | P45452 | 3/20 | 0.66 |
| ▸ | CASP3 | P42574 | 2/20 | 0.66 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.66 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193088 | 0.92 | NPBWR1 (0.80) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31474755 | 0.89 | NPBWR1 (0.85) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20982681 | 0.88 | NPC1 (0.73) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5566197 | 0.88 | NPC1 (0.78) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL9032997 | 0.85 | ALDH1A1 (0.62) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31474746 | 0.84 | NPC1 (0.72) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6327841 | 0.84 | NPC1 (0.72) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL3335014 | 0.83 | ALDH1A1 (0.61) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL2250050 | 0.83 | MMP2 (0.80) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL22439772 | 0.83 | NPC1 (0.79) | NPBWR1NPC1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204652-B1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (US) | 2006-05-17 | — | — | EP | disclosed |
| US-6649642-B2 | Useful in the treatment of autoimmune and other cathepsin related diseases. | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-05-08 | — | — | US | disclosed |
| EP-1204652-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2002-05-15 | — | — | EP | disclosed |
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | BEKKALI YOUNES (US) | 2001-11-15 | — | — | US | disclosed |
| US-6313117-B1 | TREATING AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2001009110-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-02-08 | — | — | WO | disclosed |
| EP-0511187-B1 | Process for the preparation of 1H-benzimidazoles | UCB SA (BE) | 1996-11-20 | — | — | EP | disclosed |
| EP-0511187-A1 | Process for the preparation of 1H-benzimidazoles | U C B, S.A. (BE) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041700-A1 | Novel succinate derivative compounds useful as cysteine protease inhibitors | SDHA, LONP1, SUCNR1 | NPBWR1 3601/4885NPC1 2336/4885MAPT 4521/4885 |
| US-20030087939-A1 | NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS | SDHA, LONP1, SUCNR1 | NPBWR1 3601/4885NPC1 2336/4885MAPT 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.